Mayba, O. | Search bioRxiv

bioRxiv2026

Joint analysis of multiply perturbed cells improves statistical power and cost efficiency in Perturb-seq

Perturb-seq measures transcriptomic responses to genetic perturbations at scale, but conventional designs that enrich for one guide RNA per cell remain resource-intensive. Standard analyses discard cells carrying multiple guides, further limiting the usable yield from each experiment. Here, we characterize how incorporating these guide multiplets affects signal recovery, information loss, and cost reduction. At the highest guide burden, cells showed increased stress and suppressed cell-cycle progression. We develop PerturbMatch, a scalable statistical framework to analyze guide multiplets. Among different classes of guide multiplets, doublets and triplets recovered perturbation responses more accurately than higher-order multiplets. Across three 5000-gene Perturb-seq screens with increasing guide loading, per-cell costs decreased by up to 81% while information loss remained within 1.5-fold of the loss observed between technical replicates. In existing genome-wide Perturb-seq data, incorporating previously discarded guide multiplets increased usable cell numbers and improved statistical power. Compared with a singlet holdout set, adding guide multiplets moved signal recovery closer to the theoretical expected reproducibility. Overall, we recommend a design that intentionally includes single-guide cells, guide doublets, and guide triplets to improve cost efficiency while preserving signal recovery.

genomics↗

bioRxiv2026

Virtual phenotypic screening discovers novel scaffolds inhibiting the PI3K/mTOR pathway

Phenotypic drug discovery has yielded many first-in-class small-molecule drugs by discovering modulators of disease phenotypes in physiologically relevant cellular systems. However, high-content phenotypic assays lack the ultra-high-throughput scalability of target-based screens. Recent advances in virtual screening present an opportunity to address this bottleneck, but have been limited to simple phenotypes like viability, restricted to small repurposing libraries, or lack in-depth biological validation. Here, we present PhenoCompass, a multimodal co-embedding model that aligns compound structures and high-content phenotypic imaging to enable virtual phenotypic screening over billion-compound libraries. Following training on the Joint Undertaking in Morphology dataset with more than 100,000 Cell Painting compound profiles, retrospective validation with historical biochemical high-throughput screening data demonstrates that PhenoCompass ranks compounds according to their biochemical target engagement. Leveraging PhenoCompass, we performed a prospective screen of 3.8 billion Enamine REAL compounds for inhibitors of PI3K/mTOR pathway, a critical signaling cascade whose aberrant activation is a common tumor driver. This search identified 11 novel compounds with pathway-consistent Cell Painting readout and diverse scaffolds, a 54-fold enrichment over the training set. Orthogonal validation experiments using a FOXO3A reporter assay and direct kinase inhibition confirmed seven structurally novel inhibitors with distinct mechanisms of action. These results highlight the convergence of diverse molecular target profiles onto a shared morphological pathway signature and establish PhenoCompass as a robust framework for high-content phenotypic virtual screening.

bioinformatics↗